Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)

NCT05529784 · clinicaltrials.gov ↗

UNKNOWN

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS